HPV-FASTER: Broadening the scope for prevention of HPV-related cancer

Nature Reviews Clinical Oncology

Volumn 13, Issue 2, 2016, Pages 119-132

  Bosch, F Xavier ^a   Robles, Claudia ^a   Díaz, Mireia ^a   Arbyn, Marc ^b   Baussano, Iacopo ^c   Clavel, Christine ^d   Ronco, Guglielmo ^e   Dillner, Joakim ^f   Lehtinen, Matti ^g   Petry, Karl Ulrich ^h   Poljak, Mario ⁱ   Kjaer, Susanne K ^j   Meijer, Chris J L M ^k   Garland, Suzanne M ^l   Salmerón, Jorge ^m   Castellsagué, Xavier ^a,n   Bruni, Laia ^a   De Sanjosé, Silvia ^a,n   Cuzick, Jack ^o  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d REIMS UNIVERSITY HOSPITAL   (France)

^e Unit of Cancer Epidemiology   (Italy)

^f KAROLINSKA INSTITUTE   (Sweden)

^g TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^h Klinikum Wolfsburg   (Germany)

ⁱ UNIVERSITY OF LJUBLJANA   (Slovenia)

^j UNIVERSITY OF COPENHAGEN   (Denmark)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY OF MELBOURNE   (Australia)

^m INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

ⁿ CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^o QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PATIENT COMPLIANCE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTECTION; REVIEW; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; VACCINATION; ADULT; COMPLICATION; EARLY CANCER DIAGNOSIS; FEMALE; IMMUNOLOGY; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; TRENDS; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

ADULT; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84955641166     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.146     Document Type: Review

References (141)

1. De Sanjose, S., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 11, 1048-1056 (2010).
2. De Sanjosé, S., et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur. J. Cancer 49, 3450-3461 (2013).
3. Alemany, L., et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur. J. Cancer 50, 2846-2854 (2014).
4. Alemany, L., et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int. J. Cancer 136, 98-107 (2015)
5. Mork, J., et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 344, 1125-1131 (2001).
6. Forman, D., et al. Global burden of human papillomavirus and related diseases. Vaccine 30 (Suppl. 5), F12-F23 (2012).
7. National Institutes of Health, National Cancer Institute. HPV and Cancer [online], http://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-Agents/hpv-fact-sheet (2015).
8. Cornall, A. M., et al. Anal and perianal squamous carcinomas and high-grade intraepithelial lesions exclusively associated with "low-risk" HPV genotypes 6 and 11. Int. J. Cancer 133, 2253-2258 (2013).
9. Ferlay, J., et al. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. WHO International Agency for Research on Cancer [online], http://globocan.iarc.fr (2010).
10. Parkin, D. M., & Bray, F. Chapter 2: The burden of HPV-related cancers. Vaccine 24 (Suppl. 3) 11-25 2006).
11. Ferlay, J., et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. WHO International Agency for Research on Cancer [online], http://globocan.iarc.fr (2013).
12. American Cancer Society. Cancer Facts and Figs 2015 [online], http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf (2015).
13. Vaccarella, S., Lortet-Tieulent, J., Plummer, M., Franceschi, S., & Bray, F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur. J. Cancer 49, 3262-3273 (2013).
14. Vaccarella, S., et al. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br. J. Cancer 111, 965-969 (2014).
15. WHO International Agency for Research on Cancer IARC Handbooks of Cancer Prevention Volume 10: Cervix Cancer Screening (IARC Press 2005).
16. Salo, H., et al. The burden and costs of prevention and management of genital disease caused by HPV in women: a population-based registry study in Finland. Int. J. Cancer 133, 1459-1469 (2013).
17. Salo, H., et al. Divergent coverage, frequency and costs of organised and opportunistic Pap testing in Finland. Int. J. Cancer 135, 204-213 (2014).
18. Habbema, D., De Kok, I. M., & Brown, M. L. Cervical cancer screening in the United States and the Netherlands: a tale of two countries. Milbank Q. 90, 5-37 (2012).
19. Arbyn, M., et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-Analysis. BMJ 337, a1284 (2008).
20. Cuzick, J., et al. New technologies and procedures for cervical cancer screening. Vaccine 30 (Suppl. 5), F107-F116 (2012).
21. Arbyn, M., et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30 (Suppl. 5), F88-F99 (2012).
22. Arbyn, M., et al. Cervical cancer screening program and human papillomavirus HPV) testing, part II: update on HPV primary screening. (Belgian Health Care Knowledge Centre [KCE], 2015).
23. Steben, M., et al. Upgrading public health programs for human papillomavirus prevention and control is possible in low- and middle-income countries. Vaccine 30 (Suppl. 5), F183-F191 (2012).
24. Meijer, C. J., et al. in The Epidemiology of Cervical Cancer and Human Papillomavirus
25. Cuzick, J., et al. Human papillomavirus testing in primary cervical screening. Lancet 345, 1533-1536 (1995).
26. Ronco, G., et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383, 524-532 (2014).
27. Cuzick, J., et al. Long-Term follow-up of cervical abnormalities among women screened by HPV testing and cytology - results from the Hammersmith study. Int. J. Cancer 122, 2294-2300 (2008).
28. Naucler, P., et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357, 1589-1597 (2007).
29. Rijkaart, D. C., et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 13, 78-88 (2012).
30. Kitchener, H. C., et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 10, 672-682 (2009).
31. Ronco, G., et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11, 249-257 (2010).
32. Wright, T. C., et al. Interlaboratory variation in the performance of liquid-based cytology: insights from the ATHENA trial. Int. J. Cancer 134, 1835-1843 (2014).
33. Franco, E. L., Mahmud, S. M., Tota, J., Ferenczy, A., & Coutlée, F. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch. Med. Res. 40, 478-485 (2009).
34. Dijkstra, M. G., et al. Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Ann. Oncol. 25, 927-935 (2014).
35. Arbyn, M., et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?. Clin. Microbiol. Infect. http://dx.doi.org/10.1016/j.cmi.2015.04.015 (2015).
36. Health Council of the Netherlands. Population screening for cervical cancer [online], http://www. gezondheidsraad.nl/sites/default/files/summaryBHMK. pdf (2011).
37. Ronco, G., et al. Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors [Italian]. Epidemiol. Prev. 36, e1-e72 (2012).
38. Torné Bladé, A., et al. Guía De cribado del cáncer De cuello De útero en España, 2014. Prog. Obstet. Ginecol. 57 (Suppl. 1), 1-53 (2014).
39. Huh, W. K., et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet. Gynecol. 125, 330-337 (2015).
40. von Karsa, L., et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. http://dx.doi.org/10.1016/j.pvr.2015.06.006 (2015).
41. US Food and Drug Administration. FDA News Release: FDA approves first human papillomavirus test for primary cervical cancer screening [online], http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394773.htm (2014).
42. Leinonen, M., et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J. Natl Cancer Inst. 101, 1612-1623 (2009).
43. Carozzi, F., et al. Use of p16 INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 9, 937-945 (2008).
44. Petry, K. U., et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki 67 dual-stained cytology. Gynecol. Oncol. 121, 505-509 (2011).
45. Uijterwaal, M. H., et al. Triaging HPV-positive women with normal cytology by p16/Ki 67 dual-stained cytology testing: baseline and longitudinal data. Int. J. Cancer 136, 2361-2368 (2015).
46. Schiffman, M., et al. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results. J. Clin. Microbiol. 53, 52-59 (2015).
47. Verhoef, V. M., et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT 3): a randomised controlled non-inferiority trial. Lancet Oncol. 15, 315-322 (2014).
48. Cuzick, J., Mayrand, M. H., Ronco, G., Snijders, P., & Wardle, J. Chapter 10: New dimensions in cervical cancer screening. Vaccine 24 (Suppl. 3), 90-97 (2006).
49. Cuzick, J., et al. Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions. J. Clin. Virol. 60, 44-49 (2014).
50. Denny, L., et al. Screen and treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA 294, 2173-2181 (2005).
51. Sankaranarayanan, R., et al. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360, 1385-1394 (2009).
52. Kyrgiou, M., et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-Analysis. Lancet 367, 489-498 (2006).
53. McCaffery, K., Waller, J., Nazroo, J., & Wardle, J. Social and psychological impact of HPV testing in cervical screening: a qualitative study. Sex. Transm. Infect. 82, 169-174 (2006).
54. Kwan, T. T., et al. Psychological burden of testing positive for high-risk human papillomavirus on women with atypical cervical cytology: a prospective study. Acta Obstet. Gynecol. Scand. 90, 445-451 (2011).
55. Hendry, M., et al. Are women ready for the new cervical screening protocol in England?. A systematic review and qualitative synthesis of views about human papillomavirus testing. Br. J. Cancer 107, 243-254 (2012).
56. Qiao, Y. L., et al. Lower cost strategies for triage of human papillomavirus DNA-positive women. Int. J. Cancer 134, 2891-2901 (2014).
57. Chen, W., et al. The concordance of HPV DNA detection by Hybrid Capture 2 and careHPV on clinician- and self-collected specimens. J. Clin. Virol. 61, 553-557 (2014).
58. Arbyn, M., et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-Analysis. Lancet Oncol. 15, 172-183 (2014).
59. Pathak, N., Dodds, J., Zamora, J., & Khan, K. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-Analysis. BMJ 349, g5264 (2014).
60. Castle, P. E., et al. Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral population. Am. J. Clin. Pathol. 143, 126-133 (2015).
61. Schiller, J. T., Castellsagué, X., & Garland, S. M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30 (Suppl. 5), F123-F138 (2012).
62. Lehtinen, M., & Dillner, J. Clinical trials of human papillomavirus vaccines and beyond. Nat. Rev. Clin. Oncol. 10, 400-410 (2013).
63. Stillo, M., Carrillo Santisteve, P., & Lopalco, P. L. Safety of human papillomavirus vaccines: a review. Expert Opin. Drug Saf. 14, 697-712 (2015).
64. US Food and Drug Administration June 8 2006 Approval Letter: Human Papillomavirus Quadrivalent Types 6, 11, 16, 18) Vaccine, Recombinant [online], http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm111283.htm (2006).
65. Herrero, R., et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS ONE 8, e68329 (2013).
66. Garland, S. M. The Australian experience with the human papillomavirus vaccine. Clin. Ther. 36, 17-23 (2014).
67. Hariri, S., et al. Reduction in HPV 16/18 associated high grade cervical lesions following HPV vaccine introduction in the United States-2008-2012. Vaccine 33, 1608-1613 (2015).
68. Baldur-Felskov, B., Dehlendorff, C., Munk, C., & Kjaer, S. K. Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women. J. Natl Cancer Inst. 106, djt460 (2014).
69. Joura, E. A., et al. A 9 valent HPV vaccine against infection and intraepithelial neoplasia in women. N. Engl. J. Med. 372, 711-723 (2015).
70. Drolet, M., et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-Analysis. Lancet Infect. Dis. 15, 565-580 (2015).
71. Tabrizi, S. N., et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect. Dis. 14, 958-966 (2014).
72. Guan, P., et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-Analysis from cervical infection to cancer. Int. J. Cancer 131, 2349-2359 (2012).
73. For prevention of certain cancers caused by five additional types of HPV [online], http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485.htm (2014).
74. European Medicines Agency. Gardasil 9 [online], http://www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/human/medicines/003852/human-med-001863. jsp&mid=WC0b01ac058001d124 (2015).
75. Lehtinen, M., et al. Overall efficacy of HPV 16/18 AS04 adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4 year end of study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13, 89-99 (2012).
76. Mesher, D., et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine 32, 26-32 (2013).
77. Malagón, T., et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-Analysis. Medicine (Baltimore) 94, e722 (2015).
78. David, M. P., et al. Long-Term persistence of anti HPV 16 and 18 antibodies induced by vaccination with the AS04 adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol. Oncol. 115, S1-S6 (2009).
79. Aregay, M., Shkedy, Z., Molenberghs, G., David, M. P., & Tibaldi, F. Model-based estimates of long-Term persistence of induced HPV antibodies: a flexible subject-specific approach. J. Biopharm. Stat. 23, 1228-1248 (2013).
80. Markowitz, L. E., et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 56, 1-24 (2007).
81. Giuliano, A. R., et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N. Engl. J. Med. 364, 401-411 (2011).
82. Palefsky, J. M., et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N. Engl. J. Med. 365, 1576-1585 (2011).
83. Castellsagué, X., et al. End of study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br. J. Cancer 105, 28-37 (2011).
84. Skinner, S. R., et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04 adjuvanted vaccine in women older than 25 years: 4 year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet 384, 2213-2227 (2014).
85. Kim, J. J., Brisson, M., Edmunds, W. J., & Goldie, S. J. Modeling cervical cancer prevention in developed countries. Vaccine 26 (Suppl. 10), K76-K86 (2008).
86. Markowitz, L. E., et al. Human papillomavirus vaccine introduction-The first five years. Vaccine 30 (Suppl. 5), F139-F148 (2012).
87. Elfström, K. M., Dillner, J., & Arnheim Dahlström, L. Organization and quality of HPV vaccination programs in Europe. Vaccine 33, 1673-1681 (2015).
88. Franco, E. L., Cuzick, J., Hildesheim, A., & De Sanjosé, S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24 (Suppl. 3), 171-177 (2006).
89. Tota, J. E., Ramana-Kumar, A. V., El-Khatib, Z., & Franco, E. L. The road ahead for cervical cancer prevention and control. Curr. Oncol. 21, e255-e264 (2014).
90. Kjaer, S. K., Frederiksen, K., Munk, C., & Iftner, T. Long-Term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J. Natl Cancer Inst. 102, 1478-1488 (2010).
91. De Sanjose, S., et al. Age-specific occurrence of HPV16- and HPV18 related cervical cancer. Cancer Epidemiol. Biomarkers Prev. 22, 1313-1318 (2013).
92. GAVI: The Vaccine Alliance Human papillomavirus vaccine support [online], http://www.gavi.org/support/nvs/human-papillomavirus-vaccine-support/(2015).
93. [No authors listed] Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol. Rec. 89, 465-491 (2014).
94. Hildesheim, A., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298, 743-753 (2007).
95. Gertig, D. M., et al. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 11, 227 (2013).
96. Lehtinen, M., et al. Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial. Vaccine 33, 1284-1290 (2015).
97. Edgren, G., & Sparén, P. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol. 8, 311-316 (2007).
98. Kang, W. D., Choi, H. S., & Kim, S. M. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?. Gynecol. Oncol. 130, 264-268 (2013).
99. Australian Government. Medical Services Advisory Committee, Standing Committee on Screening. MSAC Outcomes: Application no. 1276 - renewal of the National Cervical Screening Program [online], http://www.msac.gov.au/internet/msac/publishing.nsf/Content/FD36D6990FFAA639 CA25799200058940/$File/1276%20-% 20Final%20MSAC%20PSD%20-%20NCSP% 20Renewal.pdf (2014).
100. Rodríguez, A. C., et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J. Natl Cancer Inst. 102, 315-324 (2010).
101. Castañón, A., Landy, R., Cuzick, J., & Sasieni, P. Cervical screening at age 50-64 years and the risk of cervical cancer at age 65 years and older: population-based case control study. PLoS Med. 11, e1001585 (2014).
102. Gravitt, P. E. The known unknowns of HPV natural history. J. Clin. Invest. 121, 4593-4599 (2011).
103. Gravitt, P. E. Evidence and impact of human papillomavirus latency. Open Virol. J. 6, 198-203 (2012).
104. Trottier, H., et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res. 70, 8569-8577 (2010).
105. Veldhuijzen, N. J., Snijders, P. J., Reiss, P., Meijer, C. J., & Van De Wijgert, J. H. Factors affecting transmission of mucosal human papillomavirus. Lancet Infect. Dis. 10, 862-874 (2010).
106. Safaeian, M., et al. Epidemiological study of anti HPV16/18 seropositivity and subsequent risk of HPV16 and 18 infections. J. Natl Cancer Inst. 102, 1653-1662 (2010).
107. Castellsagué, X., et al. Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA. J. Infect. Dis. 210, 517-534 (2014).
108. Dempsey, A. F., Brewer, S. E., Pyrzanowski, J., Sevick, C., & O'leary, S. T. Acceptability of human papillomavirus vaccines among women older than 26 years. Vaccine 33, 1556-1561 (2015).
109. Marshall, H., Ryan, P., Roberton, D., & Baghurst, P. A cross-sectional survey to assess community attitudes to introduction of human papillomavirus vaccine. Aust. N. Z. J. Public Health 31, 235-242 (2007).
110. Cui, Y., Baldwin, S. B., Wiley, D. J., & Fielding, J. E. Human papillomavirus vaccine among adult women: disparities in awareness and acceptance. Am. J. Prev. Med. 39, 559-563 (2010).
111. Agorastos, T., et al. Distinct demographic factors influence the acceptance of vaccination against HPV. Arch. Gynecol. Obstet. 292, 197-205 (2015).
112. Anhang Price, R., Koshiol, J., Kobrin, S., & Tiro, J. A. Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine. Vaccine 29, 4238-4243 (2011).
113. Lazcano-Ponce, E., Alonso, P., Ruiz-Moreno, J. A., & Hernández-Avila, M. Recommendations for cervical cancer screening programs in developing countries. The need for equity and technological development. Salud Pública México 45 (Suppl. 3), S449-S462 (2003).
114. Almonte, M., et al. New paradigms and challenges in cervical cancer prevention and control in Latin America [Spanish]. Salud Pública México 52, 544-559 (2010).
115. Poljak, M., et al. Recommendations for cervical cancer prevention in Central and Eastern Europe and Central Asia. Vaccine 31 (Suppl. 7), H80-H82 (2013).
116. Dasbach, E. J., Largeron, N., & Elbasha, E. H. Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model. Expert Rev. Pharmacoecon. Outcomes Res. 8, 491-500 (2008).
117. Kim, J. J., & Goldie, S. J. Health and economic implications of HPV vaccination in the United States. N. Engl. J. Med. 359, 821-832 (2008).
118. Usher, C., et al. Cqnost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine 26, 5654-5661 (2008).
119. Dasbach, E. J., Insinga, R. P., & Elbasha, E. H. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 115, 947-956 (2008).
120. Jit, M., Choi, Y. H., & Edmunds, W. J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337, a769 (2008).
121. Kim, J. J., Ortendahl, J., & Goldie, S. J. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann. Intern. Med. 151, 538-545 (2009).
122. Elbasha, E. H., Dasbach, E. J., Insinga, R. P., Haupt, R. M., & Barr, E. Age-based programs for vaccination against HPV. Value Health 12, 697-707 (2009).
123. Dasbach, E. J., Nagy, L., Brandtmüller, A., & Elbasha, E. H. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. J. Med. Econ. 13, 110-118 (2010).
124. Olsen, J., & Jepsen, M. R. Human papillomavirus transmission and cost-effectiveness of qnintroducing quadrivalent HPV vaccination in Denmark. Int. J. Technol. Assess. Health Care 26, 183-191 (2010).
125. Westra, T. A., et al. Until which age should women be vaccinated against HPV infection?. Recommendation based on cost-effectiveness analyses. J. Infect. Dis. 204, 377-384 (2011).
126. Demarteau, N., Detournay, B., Tehard, B., El Hasnaoui, A., & Standaert, B. A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. Int. J. Public Health 56, 153-162 (2011).
127. Bogaards, J. A., Coupé, V. M. H., Meijer, C. J. L. M., & Berkhof, J. The clinical benefit andcost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands. Vaccine 29, 8929-8936 (2011).
128. Demarteau, N., Van Kriekinge, G., & Simon, P. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre and post-sexual debut in Belgium. Vaccine 31, 3962-3971 (2013).
129. Turner, H. C., Baussano, I., & Garnett, G. P. Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine. PLoS ONE 8, e75552 (2013).
130. Baussano, I., Lazzarato, F., Ronco, G., Dillner, J., & Franceschi, S. Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries. Int. J. Cancer 133, 1876-1881 (2013).
131. Baussano, I., Dillner, J., Lazzarato, F., Ronco, G., & Franceschi, S. Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. Infect. Agent. Cancer 9, 4 (2014).
132. Burger, E. A., Sy, S., Nygård, M., Kristiansen, I. S., & Kim, J. J. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-Adolescent boys. PLoS ONE 9, e89974 (2014).
133. Jit, M., Brisson, M., Laprise, J. F., & Choi, Y. H. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ 350, g7584 (2015).
134. Cervical cancer prevention. Cervical cancer prevention in Europe: CoheaHr [online], http://www.coheahr.eu/(2015).
135. Lazcano-Ponce, E., et al. Specimen self-collection and HPV DNA screening in a pilot study of 100,242 women. Int. J. Cancer 135, 109-116 (2014).
136. US National Library of Medicine ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02510027 (2015).
137. HPV 2015. 30th International Papillomavirus Conference, September 17-21, 2015, Lisbon, Portugal [online], http://www.hpv2015.org/(2015).
138. Bruni, L., et al. Cervical human papillomavirus prevalence in 5 continents: meta-Analysis of 1 million women with normal cytological findings. J. Infect. Dis. 202, 1789-1799 (2010).
139. Kyrgiou, M., et al. The up to date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: the Cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach. Cancer Treat. Rev. 32, 516-523 (2006).
140. McCredie, M. R., et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 9, 425-434 (2008).
141. Muñoz, N., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 373, 1949-1957 (2009).